Esperion Therapeutics ESPR 深 沪
已收盘 09-19 16:00:00 美东时间
2.66
-0.090
-3.27%
华盛通- 最 高2.9399
- 今 开2.83
- 成交量 1073.39万股
- 最 低 2.65
- 昨 收 2.75
- 总市值 5.37亿
- 52周最高 3.94
- 市盈率 静 --
- 换手率 5.31%
- 52周最低 0.6925
- 委 比 -70.92%
- 总股本 2.02亿
- 历史最高 120.96
- 量 比 2.05
- 振 幅 10.54%
- 历史最低 0.6925
- 每 手 1
- 风险率 0.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Esperion announced that its partner, Otsuka Pharmaceutical, has received approval in Japan to market NEXLETOL for hypercholesterolemia and familial hypercholesterolemia. This marks a major milestone in Esperion's international growth strategy, as Japan is one of the top three global markets for cardiovascular prevention. With NEXLETOL now approved in the U.S., Europe, and Japan, Esperion has expanded access to its non-statin LDL-C lowering therap...
09-19 12:00
Espey Mfg. & Electronics Corp. reports fourth quarter and year-end results
Espey Mfg. & Electronics Corp. reported fiscal year 2025 net sales of $43.95 million, up 13% from $38.74 million in 2024, with net income rising 39% to $8.14 million ($3.02 per diluted share) from $5.82 million ($2.29 per diluted share). Fourth quarter 2025 net sales were $9.60 million versus $11.61 million last year, with net income up 55% to $2.93 million ($1.05 per diluted share) from $1.89 million ($0.73 per diluted share). The company ended ...
09-16 20:05
Top 2 Health Care Stocks That May Plunge This Month
As of Sept. 5, 2025, two stocks in the health care sector could be flashing a r...
09-05 22:39
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
<p>Esperion welcomed the inclusion of bempedoic acid as the only non-statin therapy newly recommended for LDL-C lowering and cardiovascular risk reduction in the 2025 ESC/EAS guidelines. The guidelines highlight the use of non-statin therapies, particularly bempedoic acid, for patients unable to take statins, and recommend its addition to maximally tolerated statin therapy for high-risk patients. Esperion noted the guidelines affirm their strateg...
08-29 12:00
Esperion to Participate in Upcoming September Investor Conferences
Esperion Therapeutics will participate in two webcasted investor events in September 2025: the Cantor Global Healthcare Conference on September 3 and the H.C. Wainwright Global Investment Conference on September 8. Both events will be live-streamed on Esperion's investor website, with replays available for approximately 90 days. Esperion is a commercial-stage biopharmaceutical company focused on developing novel, non-statin lipid-lowering therapi...
08-26 12:00
Esperion Delays Q2 2025 Financial Report Filing
Esperion ( ($ESPR) ) has released a notification of late filing. Esperion Thera...
08-12 06:08
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion granted 12 new employees 73,500 restricted stock units (RSUs) under its 2017 Inducement Equity Incentive Plan on August 5, 2025. The RSUs vest over four years, with 25% vesting after one year and the remaining 75% vesting quarterly over the next three years, contingent on continued employment. Esperion Therapeutics is a biopharmaceutical company developing innovative treatments for cardiovascular diseases, including once-daily non-statin...
08-07 21:30
Esperion rises after revenue beat, Q1 profitability expectation
Esperion Therapeutics (NASDAQ:ESPR) shares rose on Tuesday after the company reported second quarter revenue above estimates, and now expects to achieve sustainable profitability beginning in the firs...
08-05 23:53
Esperion Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
Esperion Therapeutics shares are trading higher after the company reported bett...
08-05 20:51
Esperion Therapeutics Q2 EPS $(0.02) Beats $(0.14) Estimate, Sales $82.385M Beat $63.142M Estimate
Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.14) by 85.51 percent. This is a 93.94 percent increase over losses of $(0.33) per share
08-05 18:01
